MDAI

Company Overview — What Does Spectral AI, Inc. Do?

Spectral AI, Inc. operates as an artificial intelligence (AI) company. The company focuses on medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView, a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. The company is based in Dallas, Texas. Spectral AI, Inc. (MDAI) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Wensheng Fan and employs approximately 83 people. With a market capitalization of $46M, MDAI is one of the notable companies in the Healthcare sector.

Spectral AI, Inc. (MDAI) Stock Rating — Reduce (April 2026)

As of April 2026, Spectral AI, Inc. receives a Reduce rating with a composite score of 30.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.MDAI ranks #3,544 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Spectral AI, Inc. ranks #561 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MDAI Stock Price and 52-Week Range

Spectral AI, Inc. (MDAI) currently trades at $1.72. The stock gained $0.05 (3.0%) in the most recent trading session. The 52-week high for MDAI is $3.21, which means the stock is currently trading -46.4% from its annual peak. The 52-week low is $1.04, putting the stock 65.4% above its annual trough. Recent trading volume was 486K shares, suggesting relatively thin trading activity.

Is MDAI Overvalued or Undervalued? — Valuation Analysis

Spectral AI, Inc. (MDAI) carries a value factor score of 21/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 2.20x, compared to 1.66x for the average Healthcare stock.

At current multiples, Spectral AI, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Spectral AI, Inc. Profitability — ROE, Margins, and Quality Score

Spectral AI, Inc. (MDAI) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 261.0%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at -47.3% versus the sector average of -33.1%.

On a margin basis, Spectral AI, Inc. reports gross margins of 45.0%, compared to 71.5% for the sector. The operating margin is -38.6% (sector: -66.1%). Net profit margin stands at -56.5%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -49.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MDAI Debt, Balance Sheet, and Financial Health

Spectral AI, Inc. has a debt-to-equity ratio of -95.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.94x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $9M. Cash and equivalents stand at $10M.

MDAI has a beta of 0.96, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Spectral AI, Inc. is 32/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Spectral AI, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Spectral AI, Inc. reported revenue of $24M and earnings per share (EPS) of $-0.29. Net income for the quarter was $-10M. Gross margin was 45.0%. Operating income came in at $-7M.

In FY 2025, Spectral AI, Inc. reported revenue of $20M and earnings per share (EPS) of $-0.29. Net income for the quarter was $-8M. Gross margin was 45.4%. Revenue grew -33.6% year-over-year compared to FY 2024. Operating income came in at $-9M.

In Q3 2025, Spectral AI, Inc. reported revenue of $4M and earnings per share (EPS) of $-0.13. Net income for the quarter was $-4M. Gross margin was 42.8%. Revenue grew -53.6% year-over-year compared to Q3 2024. Operating income came in at $-3M.

In Q2 2025, Spectral AI, Inc. reported revenue of $5M and earnings per share (EPS) of $-0.31. Net income for the quarter was $-8M. Gross margin was 45.2%. Revenue grew -32.3% year-over-year compared to Q2 2024. Operating income came in at $-2M.

Over the past 8 quarters, Spectral AI, Inc. has demonstrated a growth trajectory, with revenue expanding from $7M to $24M. Investors analyzing MDAI stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MDAI Dividend Yield and Income Analysis

Spectral AI, Inc. (MDAI) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MDAI Momentum and Technical Analysis Profile

Spectral AI, Inc. (MDAI) has a momentum factor score of 29/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 61/100 reflects moderate short selling activity.

MDAI vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Spectral AI, Inc. (MDAI) ranks #561 out of 838 stocks based on the Blank Capital composite score. This places MDAI in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MDAI against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MDAI vs S&P 500 (SPY) comparison to assess how Spectral AI, Inc. stacks up against the broader market across all factor dimensions.

MDAI Next Earnings Date

No upcoming earnings date has been announced for Spectral AI, Inc. (MDAI) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MDAI? — Investment Thesis Summary

The quantitative profile for Spectral AI, Inc. suggests caution. The quality score of 24/100 flags below-average profitability. The value score of 21/100 indicates premium valuation. Momentum is weak at 29/100, a headwind for near-term performance. High volatility (stability score 32/100) increases portfolio risk.

In summary, Spectral AI, Inc. (MDAI) earns a Reduce rating with a composite score of 30.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MDAI stock.

Related Resources for MDAI Investors

Explore more research and tools: MDAI vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MDAI head-to-head with peers: MDAI vs AZN, MDAI vs SLGL, MDAI vs VMD.